TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28597253

Group type: EXPERIMENTAL
Intervention: Standardized patient education program provided by specially trained oncology nurses
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard care (usual oncologist counseling)
Number of subjects: 165
Study: 25911546

Group type: EXPERIMENTAL
Intervention: Misoprostol 2 hours after mifepristone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Misoprostol 48 hours after mifepristone
Number of subjects: 100
Study: 23406684

Group type: EXPERIMENTAL
Intervention: 3-day home blood pressure monitoring (HBPM) protocol
Number of subjects: 158

Group type: COMPARATOR
Intervention: 5-day home blood pressure monitoring (HBPM) protocol
Number of subjects: 158
Study: 21346616

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quetiapine 1200 mg/d
Number of subjects: 60
Study: 19858437

Group type: EXPERIMENTAL
Intervention: Intensive intervention (NCM and CHW team)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Intensive intervention (NCM and CHW team) with most visits
Number of subjects: 542

Group type: COMPARATOR
Intervention: Minimal intervention (mailings and telephone calls)
Number of subjects: 542
Study: 17581217

Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg/day, p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal subjects with premature ventricular beats, no structural heart disease)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCM (untreated)
Number of subjects: 0
Study: 15699266

Group type: EXPERIMENTAL
Intervention: avasimibe 750 mg QDS for 8 weeks
Number of subjects: 21
Study: 11984291

Group type: EXPERIMENTAL
Intervention: 3-week wheelchair practice period on a computer-controlled wheelchair ergometer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (only participated in trials 1 and 9)
Number of subjects: 20
Study: 10544534

Group type: EXPERIMENTAL
Intervention: nasally administered continuous positive airway pressure (CPAP) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: recent technological developments in CPAP therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: semiattended and unattended settings for CPAP therapy
Number of subjects: 0
Study: 8553353

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography (Doppler) observation
Number of subjects: 55
Study: 2272957

Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone and pyruvate (DHAP) supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Polycose)
Number of subjects: 8
Study: 7377861

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 48

Group type: COMPARATOR
Intervention: No levamisole or placebo (Control)
Number of subjects: 48
Study: 31438849

Group type: EXPERIMENTAL
Intervention: Prewarming at 43 °C during epidural catheter placement
Number of subjects: 47

Group type: COMPARATOR
Intervention: No prewarming
Number of subjects: 47
Study: 28185468

Group type: EXPERIMENTAL
Intervention: Early precut (group A)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Pancreatic duct stent (group B)
Number of subjects: 101
Study: 26562491

Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the PLEASANT trial
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Previous randomised controlled trial involvement
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Number of studies a practice had previously engaged in
Number of subjects: 142

Group type: COMPARATOR
Intervention: Practice size
Number of subjects: 142
Study: 23123345

Group type: EXPERIMENTAL
Intervention: Doxycycline (200mg/day) for 23 days followed by doxycycline (200mg/day) in combination with albendazole (ABZ) (400mg/day) for 7 days
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Doxycycline (200mg/day) alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) (400mg/day) alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Doxycycline combined with ABZ
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 7-day regimen of ABZ
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Doxycycline and ABZ in combination
Number of subjects: 68
Study: 21785478

Group type: EXPERIMENTAL
Intervention: Retrodiscal approach TFESI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classic approach TFESI
Number of subjects: 40
Study: 19514296

Group type: EXPERIMENTAL
Intervention: Combined therapeutic modalities with magnetopuncture therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined therapeutic modalities without magnetopuncture therapy
Number of subjects: 0
Study: 16691061

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate (CS) gel
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 59
Study: 15585061

Group type: EXPERIMENTAL
Intervention: Half‐day critical appraisal skills training workshop
Number of subjects: 145

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 145
Study: 11350571

Group type: EXPERIMENTAL
Intervention: High-dose nimodipine (2-mg h(-1))
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Low-dose nimodipine (1-mg h(-1))
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 8498421

Group type: EXPERIMENTAL
Intervention: 587 mg calcium per day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1336 mg calcium per day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 mg manganese per day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5.6 mg manganese per day
Number of subjects: 10
Study: 2958819

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg intramuscularly and intravenously
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 276
Study: 31885292

Group type: EXPERIMENTAL
Intervention: Readmitted patients (5.29% of total population)
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: History of eczema
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: Positive mycoplasma pneumoniae (MP) antibody IgM
Number of subjects: 1702
Study: 31913413

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel alone or with carboplatin and/or veliparib for 12 weeks followed by 4 cycles of doxorubicin hydrochloride and cyclophosphamide
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel alone or with carboplatin and/or veliparib
Number of subjects: 634
Study: 30231642

Group type: EXPERIMENTAL
Intervention: AAC training for peers
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study: 27846875

Group type: EXPERIMENTAL
Intervention: Direct anterior approach for THA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posterolateral approach for THA
Number of subjects: 0
Study: 25372086

Group type: EXPERIMENTAL
Intervention: Combination therapy (25 mg etanercept plus methotrexate)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 23055132

Group type: EXPERIMENTAL
Intervention: Group training (GT)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Individual training (IT)
Number of subjects: 124
Study: 21740612

Group type: EXPERIMENTAL
Intervention: Increased brain activity in left supramarginal and angular gyri, superior and middle temporal gyri in Adequate Responders (AR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline activation profiles of AR group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 18637924

Group type: EXPERIMENTAL
Intervention: Karydakis procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Limberg procedure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 100
Study: 16549707

Group type: EXPERIMENTAL
Intervention: 3-injection site pattern (3 injections of 10 U of botulinum toxin A)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 5-injection site pattern (5 injections of 10 U of botulinum toxin A)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (3 injections)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (5 injections)
Number of subjects: 221
Study: 12892319

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oils
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study: 11156724

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of enoxaparin and abciximab
Number of subjects: 0
Study: 9052285

Group type: EXPERIMENTAL
Intervention: 16 mg of dexamethasone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 38
Study: 8112474

Group type: EXPERIMENTAL
Intervention: Sedation with no supplemental oxygen
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: No sedation and no oxygen supplementation
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Sedation and supplemental oxygen
Number of subjects: 212

Group type: COMPARATOR
Intervention: No sedation but supplemental oxygen
Number of subjects: 212
Study: 3061292

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus prednisone (C+P)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Azathioprine plus prednisone (A+P)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cyclophosphamide (C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30990088

Group type: EXPERIMENTAL
Intervention: Group parent and adolescent skills training (STAND)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dyadic skills training blended with motivational interviewing (STAND)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Group models (STAND)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Dyadic treatment (STAND)
Number of subjects: 123
Study: 29091530

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 60% of 1-repetition maximum
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 72% of 1-repetition maximum
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% of 1-repetition maximum
Number of subjects: 11
Study: 27197965

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS) calculated from 29 prostate cancer risk-associated SNPs
Number of subjects: 4528

Group type: COMPARATOR
Intervention: Family History (FH)
Number of subjects: 4528

Group type: EXPERIMENTAL
Intervention: FH+ or GRS >1.4
Number of subjects: 4528

Group type: EXPERIMENTAL
Intervention: Targeting FH+ or GRS >1.4 men
Number of subjects: 4528
Study: 25564411

Group type: COMPARATOR
Intervention: Hepatectomy alone (Group A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hepatectomy combined with lymphadenectomy (Group B)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Surgical complications (Group A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Surgical complications (Group B)
Number of subjects: 85
Study: 23759461

Group type: EXPERIMENTAL
Intervention: Metformin 1,500 mg/d
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 19796088

Group type: EXPERIMENTAL
Intervention: Li-PDT-PC (5-ALA 0.5% liposomal spray and intense pulsed light in combination with topical peeling agents)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Li-PDT-PC-AT (Li-PDT-PC with additional topical or systemic antibiotics)
Number of subjects: 32
Study: 18428095

Group type: EXPERIMENTAL
Intervention: Medication treatment plus three-weekly CM sessions for 5 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: CM sessions
Number of subjects: 43
Study: 16804925

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior chemotherapy
Number of subjects: 0
Study: 12563672

Group type: EXPERIMENTAL
Intervention: Anakinra (0.04, 0.1, 0.4, 1, or 2 mg/kg once daily for 24 weeks)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo (in addition to MTX 15 to 25 mg/wk)
Number of subjects: 419
Study: 10100069

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to famine during late gestation (n = 120)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to famine during mid-gestation (n = 109)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to famine during early gestation (n = 68)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Unexposed subjects (n = 442)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Birth weight increase
Number of subjects: 739
Study: 9156926

Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 30
Study: 1862257

Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg t.i.d.) for 8 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6814281

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31693746

Group type: EXPERIMENTAL
Intervention: Cerebral monitoring awareness (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mean arterial pressure treatment only (Group 1)
Number of subjects: 80
Study: 31527283

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 370771

Group type: EXPERIMENTAL
Intervention: Automobile speed propensity
Number of subjects: 370771

Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 370771
Study: 28422369

Group type: EXPERIMENTAL
Intervention: Short questionnaire (4 A4 pages)
Number of subjects: 4241

Group type: COMPARATOR
Intervention: Long questionnaire (7 A4 pages)
Number of subjects: 4241

Group type: EXPERIMENTAL
Intervention: £2.50 shop voucher incentive
Number of subjects: 4241

Group type: EXPERIMENTAL
Intervention: £5.00 shop voucher incentive
Number of subjects: 4241

Group type: EXPERIMENTAL
Intervention: £250 shop voucher prize draw incentive
Number of subjects: 4241

Group type: COMPARATOR
Intervention: No monetary incentive
Number of subjects: 4241
Study: 25885923

Group type: EXPERIMENTAL
Intervention: Pricing intervention (10-30% price discount on selected healthier food items)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Communications intervention (visual and interactive materials to promote healthy items)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Combined intervention (pricing and communications)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 360
Study: 24059983

Group type: EXPERIMENTAL
Intervention: Intensive integrative language therapy (at least 2 hours/day and at least 10 hours/week for at least three weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waiting list control group (untreated)
Number of subjects: 126
Study: 21410882

Group type: EXPERIMENTAL
Intervention: Fortified complementary or replacement foods provided free of charge
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Health worker advice
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: International HIV and infant feeding recommendations
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Replacement feeding
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Qualitative factors affecting decisions
Number of subjects: 811
Study: 19522426

Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin 850 mg two times a day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 32
Study: 17308899

Group type: EXPERIMENTAL
Intervention: Olpadronate (10 mg/m2/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 14973308

Group type: EXPERIMENTAL
Intervention: PNU-96391 1 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-96391 3 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-96391 10 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-96391 30 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-96391 100 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-96391 150 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-96391 200 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-96391
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PNU-100014 (metabolite)
Number of subjects: 53
Study: 11676271

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 104
Study: 9054234

Group type: EXPERIMENTAL
Intervention: 21-mg/day nicotine patches
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: 14-mg/day nicotine patches
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: 7-mg/day nicotine patches
Number of subjects: 522
Study: 7946592

Group type: EXPERIMENTAL
Intervention: CAF + MPA therapy (CAF: CPA 100 mg orally days 1-14, ADR 30 mg/m2 i.v. days 1 and 8, 5-FU 500 mg/m2 i.v. days 1 and 8; MPA 1200 mg daily)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: CAF + MPA therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: CAF therapy (control)
Number of subjects: 168
Study: 2840000

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 20
Study: 31868099

Group type: EXPERIMENTAL
Intervention: 10% velocity loss
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20% velocity loss
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30% velocity loss
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ) variables
Number of subjects: 12
Study: 29439648

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 5/5 µg
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 2.5/5 µg
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 28940037

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combined exercise (resistance and plyometric exercise)
Number of subjects: 18
Study: 26303634

Group type: COMPARATOR
Intervention: Weekend admission
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Non-weekend admission
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Thursday/Friday Norwood procedure
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Prenatally diagnosed infants born on the weekend
Number of subjects: 533
Study: 23008090

Group type: EXPERIMENTAL
Intervention: Fingertip SMBG
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Palm SMBG
Number of subjects: 137

Group type: COMPARATOR
Intervention: No SMBG
Number of subjects: 137
Study: 21633921

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of circulating progenitor cells (CPC) or bone marrow-derived progenitor cells (BMC)
Number of subjects: 59
Study: 18350925

Group type: EXPERIMENTAL
Intervention: Orthotopic cardiac transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive surgical management for secondary cardiac involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy, radiotherapy, and surgery
Number of subjects: 0
Study: 16292634

Group type: EXPERIMENTAL
Intervention: Spine Tango registry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study: 12727705

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12388895

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0
Study: 8840060

Group type: EXPERIMENTAL
Intervention: 5% sevoflurane inspired in oxygen
Number of subjects: 29
Study: 1516461

Group type: EXPERIMENTAL
Intervention: 20 mg/kg cefetamet syrup, given orally twice daily for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20 mg/kg cefaclor, given orally twice daily for 7 days
Number of subjects: 40
Study: 6237051

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31223101

Group type: EXPERIMENTAL
Intervention: Multisite intervention studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre‐post observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 0
Study: 29691951

Group type: EXPERIMENTAL
Intervention: Physiotherapy sessions, 50 minutes, 5 days/week for 4 weeks
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (4 subjects)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 3
Study: 26912469

Group type: EXPERIMENTAL
Intervention: Educational intervention by pharmacists to inform patients about adverse effects of medications
Number of subjects: 87

Group type: COMPARATOR
Intervention: Patients unaware of adverse effects of medications
Number of subjects: 87
Study: 24368588

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinsing twice daily and no brushing
Number of subjects: 34

Group type: COMPARATOR
Intervention: No CHX mouth rinsing and no brushing
Number of subjects: 34
Study: 22261136

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with acromioplasty (group I)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without acromioplasty (group II)
Number of subjects: 120
Study: 20498245

Group type: EXPERIMENTAL
Intervention: MMF 3-g arm (1.5 g twice daily on days 1 to 5, then 1.0 g twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMF 2-g arm (1.0 g twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMF 3-g arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPA AUC levels <30 mg.h/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMF 3-g arm and MMF 2-g arm
Number of subjects: 0
Study: 17645881

Group type: EXPERIMENTAL
Intervention: 24 mg/min vitamin C
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: NTG
Number of subjects: 34
Study: 15935015

Group type: EXPERIMENTAL
Intervention: Yaktrax Walker (YW)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual winter footwear (UWF)
Number of subjects: 109
Study: 12623727

Group type: EXPERIMENTAL
Intervention: Vivid video reenactment of a violent crime
Number of subjects: 2

Group type: COMPARATOR
Intervention: Crime report newscast
Number of subjects: 2